Page 247 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

226 PART III Therapeutic Modalities for the Cancer Patient

64. Hall EJ, Giaccia AJ: Time, dose, and fractionation in radiotherapy. 87. Nolan MW, Kogan L, Griffin LR, et al.: Intensity-modulated and
In Hall EJ, Giaccia AJ, editors: Radiobiology for the radiologist, ed 8, image-guided radiation therapy for treatment of genitourinary car-
Philadelphia, 2019, Wolters Kluwer, pp 417–436. cinomas in dogs, J Vet Intern Med 26:987–995, 2012.
VetBooks.ir 65. Fowler JF: Fractionated radiation therapy after strandqvist, Acta 88. Potters L, Kavanagh B, Galvin JM, et al.: American Society for
Therapeutic Radiology and Oncology (ASTRO) and American
Radiol Oncol 23:209–216, 1984.
66. Dische S, Saunders MI: The CHART regimen and morbidity, Acta
Oncol 38:147–152, 1999. College of Radiology (ACR) practice guideline for the performance
of stereotactic body radiation therapy, Int J Radiat Oncol Biol Phys
67. Amdur RJ, Parsons JT, Fitzgerald LT, et al.: The effect of overall 76:326–332, 2010.
treatment time on local control in patients with adenocarcinoma of 89. Timmerman R, Galvin J, Michalski J, et al.: Accreditation and
the prostate treated with radiation therapy, Int J Radiat Oncol Biol quality assurance for Radiation Therapy Oncology Group: mul-
Phys 19:1377–1382, 1990. ticenter clinical trials using stereotactic body radiation therapy in
68. Amdur RJ, Parsons JT, Mendenhall WM, et al.: Split-course versus lung cancer, Acta Oncol 45:779–786, 2006.
continuous-course irradiation in the postoperative setting for squa- 90. Benedict SH, Yenice KM, Followill D, et al.: Stereotactic body
mous cell carcinoma of the head and neck, Int J Radiat Oncol Biol radiation therapy: the report of AAPM Task Group 101, Med Phys
Phys 17:279–285, 1989. 37:4078–4101, 2010.
69. Trotti A: Toxicity in head and neck cancer: a review of trends and 91. LaCouture TA, Xue J, Subedi G, et al.: Small bowel dose toler-
issues, Int J Radiat Oncol Biol Phys 47:1–12, 2000. ance for stereotactic body radiation therapy, Semin Radiat Oncol
70. Carsten RE, Hellyer PW, Bachand AM, et al.: Correlations between 26:157–164, 2016.
acute radiation scores and pain scores in canine radiation patients 92. Srivastava R, Asbell SO, LaCouture T, et al.: Low toxicity for lung
with cancer of the forelimb, Vet Anaesth Analg 35:355–362, 2008. tumors near the mediastinum treated with stereotactic body radia-
71. Keime-Guibert F, Napolitano M, Delattre JY: Neurological com- tion therapy, Pract Radiat Oncol 3:130–137, 2013.
plications of radiotherapy and chemotherapy, J Neurol 245:695– 93. Jang WI, Kim MS, Bae SH, et al.: High-dose stereotactic body
708, 1998. radiotherapy correlates increased local control and overall survival
72. Freeman JE, Johnston PG, Voke JM: Somnolence after prophylac- in patients with inoperable hepatocellular carcinoma, Radiat Oncol
tic cranial irradiation in children with acute lymphoblastic leukae- 8:250, 2013.
mia, Br Med J 4:523–525, 1973. 94. Nagata Y: Stereotactic body radiotherapy for early stage lung can-
73. Stewart FA, Dorr W: Milestones in normal tissue radiation biology cer, Cancer Res Treat 45:155–161, 2013.
over the past 50 years: from clonogenic cell survival to cytokine net- 95. Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body
works and back to stem cell recovery, Int J Radiat Biol 85:574–586, radiation therapy for inoperable early stage lung cancer, JAMA
2009. 303:1070–1076, 2010.
74. Dancea HC, Shareef MM, Ahmed MM: Role of radiation-induced 96. Staehler M, Bader M, Schlenker B, et al.: Single fraction radiosur-
TGF-beta signaling in cancer therapy, Mol Cell Pharmacol 1:44–56, gery for the treatment of renal tumors, J Urol 193:771–775, 2015.
2009. 97. Kim YJ, Cho KH, Kim JY, et al.: Single-dose versus fractionated
75. Anderson CR, McNiel EA, Gillette EL, et al.: Late complications stereotactic radiotherapy for brain metastases, Int J Radiat Oncol
of pelvic irradiation in 16 dogs, Vet Radiol Ultrasound 43:187–192, Biol Phys 81:483–489, 2011.
2002. 98. Wormhoudt TL, Boss MK, Lunn K, et al.: Stereotactic radiation
76. Hendee WR: Estimation of radiation risks. BEIR V and its signifi- therapy for the treatment of functional pituitary adenomas associ-
cance for medicine, JAMA 268:620–624, 1992. ated with feline acromegaly, J Vet Intern Med 32:1383–1391, 2018.
77. Kamran SC, Berrington de GA, Ng A, et al.: Therapeutic radiation 99. Dolera M, Malfassi L, Bianchi C, et al.: Frameless stereotactic volu-
and the potential risk of second malignancies, Cancer 122:1809– metric modulated arc radiotherapy of brachial plexus tumours in
1821, 2016. dogs: 10 cases, Br J Radiol 90:20160617, 2017.
78. Hall EJ, Wuu CS: Radiation-induced second cancers: the impact of 100. Swift KE, McGrath S, Nolan MW, et al.: Clinical and imaging
3D-CRT and IMRT, Int J Radiat Oncol Biol Phys 56:83–88, 2003. findings, treatments, and outcomes in 27 dogs with imaging diag-
79. Hosoya K, Poulson JM, Azuma C: Osteoradionecrosis and radia- nosed trigeminal nerve sheath tumors: a multi-center study, Vet
tion induced bone tumors following orthovoltage radiation therapy Radiol Ultrasound 58:679–689, 2017.
in dogs, Vet Radiol Ultrasound 49:189–195, 2008. 101. Kubicek L, Vanderhart D, Wirth K, et al.: Association between
80. Gillette SM, Gillette EL, Powers BE, et al.: Radiation-induced computed tomographic characteristics and fractures following ste-
osteosarcoma in dogs after external beam or intraoperative radia- reotactic radiosurgery in dogs with appendicular osteosarcoma, Vet
tion therapy, Cancer Res 50:54–57, 1990. Radiol Ultrasound 57:321–330, 2016.
81. Evans SM, LaCreta F, Helfand S, et al.: Technique, pharmacoki- 102. Fowler JF: 21 years of biologically effective dose, Br J Radiol
netics, toxicity, and efficacy of intratumoral etanidazole and radio- 83:554–568, 2010.
therapy for treatment of spontaneous feline oral squamous cell 103. Fowler JF: The linear-quadratic formula and progress in fraction-
carcinoma, Int J Radiat Oncol Biol Phys 20:703–708, 1991. ated radiotherapy, Br J Radiol 62:679–694, 1989.
82. Citrin DE, Mitchell JB: Altering the response to radiation: sensitiz- 104. Fowler JF: Short and long fractionated schedules in radiotherapy
ers and protectors, Semin Oncol 41:848–859, 2014. and a proposed improvement, Br J Radiol 60:777–779, 1987.
83. Smith TA, Kirkpatrick DR, Smith S, et al.: Radioprotective agents 105. Fowler JF: Potential for increasing the differential response between
to prevent cellular damage due to ionizing radiation, J Transl Med tumors and normal tissues: can proliferation rate be used? Int J
15:232, 2017. Radiat Oncol Biol Phys 12:641–645, 1986.
84. Salem A, Asselin MC, Reymen B, et al.: Targeting hypoxia to 106. Bedford JS: Sublethal damage, potentially lethal damage, and chro-
improve non-small cell lung cancer outcome, J Natl Cancer Inst mosomal aberrations in mammalian cells exposed to ionizing radia-
110:14–30, 2018. tions, Int J Radiat Oncol Biol Phys 21:1457–1469, 1991.
85. Schuemann J, Berbeco R, Chithrani DB, et al.: Roadmap to clini- 107. Bedford JS, Mitchell JB, Griggs HG, et al.: Radiation-induced cel-
cal use of gold nanoparticles for radiation sensitization, Int J Radiat lular reproductive death and chromosome aberrations, Radiat Res
Oncol Biol Phys 94:189–205, 2016. 76:573–586, 1978.
86. Reichert ZR, Wahl DR, Morgan MA: Translation of targeted radia- 108. Bedford JS, Cornforth MN: Relationship between the recovery
tion sensitizers into clinical trials, Semin Radiat Oncol 26:261–270, from sublethal X-ray damage and the rejoining of chromosome
2016. breaks in normal human fibroblasts, Radiat Res 11:406–423, 1987.